Wir haben ausgewählte Abstracts von unseren Partnern für Sie zusammengestellt.
AbbVie AG
RISANKIZUMAB
UPADACITINIB
- 0589 | Comparable efficacy of upadacitinib in male and female patients with axSpA: Results from the SELECT-AXIS 1 and 2 trials
- 1435 | Impact of Treatment With Upadacitinib on Non-Nociceptive Pain and Its Relevance for the Presence of Residual Symptoms in Axial Spondyloarthritis: Results from a Multicountry Observational Study
- 0895 | Impact of Glucocorticoid Tapering in Giant Cell Arteritis: Analysis From the SELECT-GCA Trial
- 0776 | Efficacy and Safety of Upadacitinib in Giant Cell Arteritis: 2-Year Results From the Re-Randomized, Double-Blind SELECT-GCA Phase 3 Trial
AstraZeneca AG
ANIFROLUMAB
- 1539 | The Impact Of Interferon Signature On Anifrolumab Efficacy And Safety In Systemic Lupus Erythematosus: A Systematic Review And Meta-analysis
- 1547 | Anifrolumab In Systemic Lupus Erythematosus With Renal Involvement: National Multicenter Registry In Clinical Practice
- 1549 | Improvement in Joint Activity in Adults with Systemic Lupus Erythematosus Treated with Anifrolumab: Results from a Real-World Cohort
- 1550 | Real-World Outcomes of Anifrolumab in Systemic Lupus Erythematosus Patients at Toronto Lupus Program
- 1552 | Treatment With Anifrolumab Prevents Long-Term Cardiovascular Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study
Johnson & Johnson
GUSELKUMAB
- 1460 | Effect of Guselkumab and IL-17 Inhibitors on Work Productivity and Activity Impairment in Psoriatic Arthritis: 6-Month Results of the PsABIOnd Observational Study
- 0577 | Persistence and Effectiveness Across PsA Patient Subgroups With Guselkumab and IL-17 Inhibitors: 6-Month Results of the PsABIOnd Observational Study
- 2373 | Effectiveness and Tolerability of Guselkumab or TNF inhibitors as Second-Line Treatment After Receiving a TNF inhibitor as First-Line Therapy to Treat Active Psoriatic Arthritis: 52-Week Interim Data from the Manhattan Study
- 2368 | Inhibition of Structural Damage Progression With Guselkumab, a Selective IL-23i, in Participants With Active PsA: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study
- 2345 | Biological Sex-Related Differences in Radiographic Progression and Relationship With Early Clinical Response: Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Biologic-Naive Participants with Active Psoriatic Arthritis Treated With Guselkumab
Novartis Pharma Schweiz AG
SECUKINUMAB
- 1462 | Five-Year Results of Secukinumab on Minimal Disease Activity (MDA) Components and the Impact of Biologic Treatment Status on Effectiveness and Safety in Patients With Psoriatic Arthritis: Real-World Data From the SERENA Study
- 1463 | Effective Prevention of Psoriatic Arthritis with Secukinumab: A 5-Year Observation from the SERENA Study
- 1447 | Long-term impact of secukinumab on the prevention of psoriatic arthritis in patients with psoriasis: a 5-year pooled analysis of the ERASURE, FIXTURE and SCULPTURE studies
- 1464 | Incidence of Major Adverse Cardiovascular Events (MACE) in Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis Patients With and Without Cardiovascular Risk Factors Treated With Secukinumab: Five-Year Safety Data from the Real-World SERENA Study
- 0589 | Time to Clinical Response to Secukinumab Across Disease Domains Among Patients with Psoriatic Arthritis: A Pooled Post Hoc Analysis of 4 Phase 3 Trials
UCB Pharma AG
BIMEKIZUMAB
- 1454 | Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update
- 1449 | Bimekizumab Demonstrated Comparable One-Year Efficacy in Male and Female Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
- 2358 | Bimekizumab Demonstrated Early and Sustained Efficacy Regardless of Baseline Characteristics in Patients with Active Psoriatic Arthritis: Pooled Post Hoc Results up to 1-Year from Two Phase 3 Studies
- 2352 | Bimekizumab Treatment Was Efficacious to 2 Years Regardless of Duration of AxSpA Symptoms: Results from Two Phase 3 Studies
- 0574 | Bimekizumab 3-Year Efficacy in Patients with Psoriasis and Risk Factors for Progression to Psoriatic Arthritis or Screening Positive for Psoriatic Arthritis